QuantRx Biomedical Corporation (QTXB)
USD 0.0
(400.0%)
USD 0.0
(400.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | - USD | 100.0% |
| 2021 | -43.38 Thousand USD | -20.46% |
| 2020 | -36.01 Thousand USD | 82.15% |
| 2019 | -201.73 Thousand USD | -50.01% |
| 2018 | -225.02 Thousand USD | 10.12% |
| 2017 | -154.31 Thousand USD | -13.65% |
| 2016 | -194.67 Thousand USD | 63.04% |
| 2015 | -349.04 Thousand USD | 25.02% |
| 2014 | -475.1 Thousand USD | -77.86% |
| 2013 | -289.8 Thousand USD | 42.92% |
| 2012 | -579.72 Thousand USD | 37.35% |
| 2011 | -487.76 Thousand USD | 84.49% |
| 2010 | -4.81 Million USD | -47.15% |
| 2009 | -2.59 Million USD | 7.39% |
| 2008 | -5.81 Million USD | 32.62% |
| 2007 | -5.69 Million USD | -462.49% |
| 2006 | 1.44 Million USD | 240.45% |
| 2005 | -1.03 Million USD | -553.37% |
| 2004 | -86.36 Thousand USD | -222.44% |
| 2003 | -45.24 Thousand USD | 19.73% |
| 2002 | -60.93 Thousand USD | 92.75% |
| 2001 | -840 Thousand USD | 51.72% |
| 2000 | -1.74 Million USD | 28.1% |
| 1999 | -2.42 Million USD | 46.58% |
| 1998 | -4.53 Million USD | -148.9% |
| 1997 | -1.82 Million USD | 56.35% |
| 1996 | -4.17 Million USD | 4.79% |
| 1995 | -4.38 Million USD | -325.24% |
| 1994 | -1.03 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q2 | - USD | 0.0% |
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | - USD | 0.0% |
| 2022 FY | - USD | 100.0% |
| 2022 Q1 | -3606.00 USD | 45.06% |
| 2022 Q2 | -26.9 Thousand USD | -645.98% |
| 2022 Q4 | - USD | 100.0% |
| 2022 Q3 | -7250.00 USD | 73.05% |
| 2021 Q3 | -8542.00 USD | 63.23% |
| 2021 Q2 | -23.23 Thousand USD | -360.29% |
| 2021 FY | - USD | -20.46% |
| 2021 Q1 | -5047.00 USD | 44.49% |
| 2021 Q4 | -6563.00 USD | 23.17% |
| 2020 Q3 | -10.69 Thousand USD | 57.97% |
| 2020 Q4 | -9092.00 USD | 14.96% |
| 2020 Q2 | -25.44 Thousand USD | -376.22% |
| 2020 Q1 | 9210.00 USD | 103.57% |
| 2020 FY | - USD | 82.15% |
| 2019 FY | - USD | -50.01% |
| 2019 Q1 | -59 Thousand USD | -395.61% |
| 2019 Q2 | -61.83 Thousand USD | -4.8% |
| 2019 Q3 | -44.87 Thousand USD | 27.42% |
| 2019 Q4 | -258.02 Thousand USD | -474.93% |
| 2018 Q3 | -25.06 Thousand USD | 69.91% |
| 2018 Q4 | 19.96 Thousand USD | 179.63% |
| 2018 Q2 | -83.29 Thousand USD | -80.75% |
| 2018 Q1 | -46.08 Thousand USD | 4.06% |
| 2018 FY | - USD | 10.12% |
| 2017 Q3 | -31.85 Thousand USD | 6.67% |
| 2017 FY | - USD | -13.65% |
| 2017 Q1 | -35.61 Thousand USD | -16.24% |
| 2017 Q2 | -34.13 Thousand USD | 4.17% |
| 2017 Q4 | -48.03 Thousand USD | -50.8% |
| 2016 FY | - USD | 63.04% |
| 2016 Q1 | -24.22 Thousand USD | 64.92% |
| 2016 Q4 | -30.63 Thousand USD | -19.03% |
| 2016 Q3 | -25.74 Thousand USD | 49.58% |
| 2016 Q2 | -51.05 Thousand USD | -110.72% |
| 2015 Q2 | -43.5 Thousand USD | 74.53% |
| 2015 FY | - USD | 25.02% |
| 2015 Q4 | -69.07 Thousand USD | 5.16% |
| 2015 Q1 | -170.79 Thousand USD | -28.98% |
| 2015 Q3 | -72.82 Thousand USD | -67.4% |
| 2014 Q3 | -79.93 Thousand USD | 47.85% |
| 2014 Q4 | -132.42 Thousand USD | -65.67% |
| 2014 Q1 | -87.69 Thousand USD | 37.99% |
| 2014 Q2 | -153.28 Thousand USD | -74.8% |
| 2014 FY | - USD | -77.86% |
| 2013 Q2 | -73.1 Thousand USD | -706.61% |
| 2013 Q3 | -43.54 Thousand USD | 40.43% |
| 2013 Q4 | -141.41 Thousand USD | -224.73% |
| 2013 Q1 | -9063.00 USD | 49.43% |
| 2013 FY | - USD | 42.92% |
| 2012 Q4 | -17.92 Thousand USD | 87.85% |
| 2012 Q2 | -173.92 Thousand USD | -35.22% |
| 2012 Q3 | -147.47 Thousand USD | 15.21% |
| 2012 Q1 | -128.62 Thousand USD | 47.9% |
| 2012 FY | - USD | 37.35% |
| 2011 Q4 | -246.9 Thousand USD | -70.25% |
| 2011 FY | - USD | 84.49% |
| 2011 Q3 | -145.02 Thousand USD | 43.06% |
| 2011 Q2 | -254.67 Thousand USD | -145.02% |
| 2011 Q1 | -103.94 Thousand USD | 96.81% |
| 2010 FY | - USD | -47.15% |
| 2010 Q3 | -740.49 Thousand USD | -116.89% |
| 2010 Q1 | -555.55 Thousand USD | 60.63% |
| 2010 Q2 | -341.42 Thousand USD | 38.54% |
| 2010 Q4 | -3.26 Million USD | -340.36% |
| 2009 Q3 | -998.55 Thousand USD | -217.04% |
| 2009 Q2 | -314.96 Thousand USD | 64.54% |
| 2009 Q4 | -1.41 Million USD | -41.3% |
| 2009 Q1 | -888.28 Thousand USD | -75.05% |
| 2009 FY | - USD | 7.39% |
| 2008 Q2 | -1.33 Million USD | -39.99% |
| 2008 Q1 | -950.53 Thousand USD | 13.3% |
| 2008 FY | - USD | 32.62% |
| 2008 Q4 | -507.44 Thousand USD | 31.97% |
| 2008 Q3 | -745.86 Thousand USD | 43.95% |
| 2007 Q3 | -1.32 Million USD | 23.42% |
| 2007 FY | - USD | -462.49% |
| 2007 Q2 | -1.73 Million USD | -58.82% |
| 2007 Q4 | -1.09 Million USD | 17.35% |
| 2007 Q1 | -1.09 Million USD | -533.34% |
| 2006 Q4 | 251.69 Thousand USD | -50.45% |
| 2006 Q2 | 1.27 Million USD | 298.33% |
| 2006 Q1 | 320.71 Thousand USD | 228.0% |
| 2006 FY | - USD | 240.45% |
| 2006 Q3 | 507.94 Thousand USD | -60.24% |
| 2005 Q3 | -520.07 Thousand USD | -142.07% |
| 2005 Q1 | -44.9 Thousand USD | 32.48% |
| 2005 Q4 | -250.55 Thousand USD | 51.82% |
| 2005 FY | - USD | -553.37% |
| 2005 Q2 | -214.84 Thousand USD | -378.51% |
| 2004 Q1 | -11.47 Thousand USD | 0.0% |
| 2004 Q2 | -3024.00 USD | 73.65% |
| 2004 Q3 | -5360.00 USD | -77.25% |
| 2004 Q4 | -66.5 Thousand USD | -1140.67% |
| 2004 FY | - USD | -222.44% |
| 2003 FY | - USD | 19.73% |
| 2002 FY | - USD | 92.75% |
| 2002 Q1 | -20 Thousand USD | 77.78% |
| 2001 Q4 | -90 Thousand USD | 47.06% |
| 2001 FY | - USD | 51.72% |
| 2001 Q3 | -170 Thousand USD | 32.0% |
| 2001 Q2 | -250 Thousand USD | 13.79% |
| 2001 Q1 | -290 Thousand USD | 32.56% |
| 2000 Q4 | -430 Thousand USD | 8.51% |
| 2000 FY | - USD | 28.1% |
| 2000 Q1 | -400 Thousand USD | 18.37% |
| 2000 Q2 | -420 Thousand USD | -5.0% |
| 2000 Q3 | -470 Thousand USD | -11.9% |
| 1999 Q4 | -490 Thousand USD | 16.95% |
| 1999 Q3 | -590 Thousand USD | 3.28% |
| 1999 Q1 | -670 Thousand USD | 46.4% |
| 1999 FY | - USD | 46.58% |
| 1999 Q2 | -610 Thousand USD | 8.96% |
| 1998 Q2 | -870 Thousand USD | 25.64% |
| 1998 Q1 | -1.17 Million USD | 27.33% |
| 1998 Q3 | -1.18 Million USD | -35.63% |
| 1998 Q4 | -1.25 Million USD | -5.93% |
| 1998 FY | - USD | -148.9% |
| 1997 Q4 | -1.61 Million USD | -123.61% |
| 1997 FY | - USD | 56.35% |
| 1997 Q3 | -720 Thousand USD | -166.06% |
| 1997 Q2 | 1.09 Million USD | 278.69% |
| 1997 Q1 | -610 Thousand USD | 59.33% |
| 1996 Q2 | -1.02 Million USD | -4.08% |
| 1996 FY | - USD | 4.79% |
| 1996 Q4 | -1.5 Million USD | -120.59% |
| 1996 Q3 | -680 Thousand USD | 33.33% |
| 1996 Q1 | -980 Thousand USD | 9.26% |
| 1995 Q3 | -980 Thousand USD | 12.5% |
| 1995 Q4 | -1.08 Million USD | -10.2% |
| 1995 Q2 | -1.12 Million USD | -20.43% |
| 1995 Q1 | -930 Thousand USD | -82.35% |
| 1995 FY | - USD | -325.24% |
| 1994 Q1 | -230 Thousand USD | 0.0% |
| 1994 Q3 | -130 Thousand USD | 18.75% |
| 1994 Q4 | -510 Thousand USD | -292.31% |
| 1994 Q2 | -160 Thousand USD | 30.43% |
| 1994 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Medical Technologies Inc. | -963.95 Thousand USD | 100.0% |
| Ansell Limited | 209.86 Million USD | 100.0% |
| Ansell Limited | 206.3 Million USD | 100.0% |
| BG Medicine, Inc. | - USD | NaN% |
| Biotage AB (publ) | 42.83 Million USD | 100.0% |
| BioLife Sciences Inc. | - USD | NaN% |
| CB Scientific, Inc. | -1.62 Million USD | 100.0% |
| Psykey, Inc. | -1.29 Million USD | 100.0% |
| ConvaTec Group Plc | 455.5 Million USD | 100.0% |
| ConvaTec Group Plc | 455.5 Million USD | 100.0% |
| Encision Inc. | -544.19 Thousand USD | 100.0% |
| Golden Valley Development, Inc | -141.81 Thousand USD | 100.0% |
| Hear AtLast Holdings, Inc. | -109.93 Thousand USD | 100.0% |
| Innovative MedTech Inc. | -7.67 Million USD | 100.0% |
| LifePoint, Inc. | -14.2 Million USD | 100.0% |
| Medite Cancer Diagnostics, Inc. | -6.18 Million USD | 100.0% |
| Paradigm Medical Industries, Inc. | -325 Thousand USD | 100.0% |
| Remedent, Inc. | -215.23 Thousand USD | 100.0% |
| Reflect Scientific, Inc. | -405.78 Thousand USD | 100.0% |
| SmileDirectClub, Inc. | -186.13 Million USD | 100.0% |
| Sector 10, Inc. | - USD | NaN% |
| Shandong Weigao Group Medical Polymer Company Limited | 447.82 Million USD | 100.0% |
| SheerVision, Inc. | -110.53 Thousand USD | 100.0% |
| United Health Products, Inc. | -2.5 Million USD | 100.0% |
| Vasamed, Inc. | -4.57 Million USD | 100.0% |
| Wearable Health Solutions, Inc. | -2.26 Million USD | 100.0% |
| Yubo International Biotech Limited | -1.17 Million USD | 100.0% |